Levi & Korsinsky announces it has commenced an investigation of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On February 17, 2016, Catalyst Pharmaceuticals announced the receipt of a “Refusal to File” letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application for Firdapse, its experimental drug treatment. According to the letter, the FDA found that the application was “not sufficiently complete.” Upon this news, shares of Catalyst Pharmaceuticals were down more than 35% on intraday trading on February 17, 2016. To obtain additional information, go to:

http://zlk.9nl.com/catalyst-pharmaceuticals-cprx

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160217006211/en/